immunotherapy

PDS Biotech Announces Publication of Positive PDS01ADC Interim Phase 2 Clinical Trial Data from Stage 1 of NCI-led Metastatic Colorectal Cancer (mCRC) Trial

78% Objective Response Rate (ORR) with PDS01ADC; Parallel trial without PDS01ADC had 35% ORR 2-year survival rate of >80%; Parallel...

Er-Kim Signs Exclusive Distribution Agreement with LEO Pharma A/S to Commercialize LOQTORZI® (toripalimab) for Nasopharyngeal and Oesophageal Cancers

Er-Kim announces exclusive partnership with LEO Pharma A/S to launch LOQTORZI® across Central and Eastern Europe, expanding access to innovative...

Trained Therapeutix Discovery’s Chief Scientific Officer, Dr. Mulder, Honored with Fellowship at the American Institute for Medical and Biological Engineering (AIMBE)

-Recognition highlights pioneering contributions to nanomedicine underpinning the company’s RIDE platformOSS, The Netherlands, April 14, 2026 (GLOBE NEWSWIRE) -- Trained...

BioNTech and DualityBio’s Antibody-Drug Conjugate Trastuzumab Pamirtecan Demonstrated Clinically Meaningful Efficacy in Patients with HER2-Expressing, Recurrent Endometrial Cancer

Trastuzumab pamirtecan, an investigational HER2-targeted antibody-drug conjugate, met the primary efficacy endpoint in a Phase 2 cohort of heavily pre-treated...

Verrica Pharmaceuticals Announces Acceptance of Late-Breaking Abstract Highlighting Potential Abscopal Effect of VP-315 for the Treatment of Basal Cell Carcinoma at the Upcoming 2026 Society for Investigative Dermatology Annual Meeting

Caris Life Sciences Introduces Multimodal AI-Powered Molecular Insight to Identify the Benefit or Harm from the Addition of Chemotherapy for NSCLC Patients

Caris AI Insights are proprietary and only available to Caris Life Sciences customers IRVING, Texas, April 8, 2026 /PRNewswire/ -- Caris...

Oncotelic Therapeutics Announces Strategic Partnership with TechForce Robotics to Commercialize PDAOAI-Enhanced GMP Robotics Platform

LOS ANGELES, April 02, 2026 (GLOBE NEWSWIRE) -- via IBN -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”), a clinical-stage...

MiNK Therapeutics Announces Abstract Acceptance for Presentation at the American Thoracic Society (ATS) 2026 International Conference

NEW YORK, April 01, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural...

error: Content is protected !!